Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony‐stimulating factor
Open Access
- 30 July 2008
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (8) , 2257-2267
Abstract
Objective: To determine whether the plasma levels of a range of inflammatory proteins have utility as biomarkers of disease activity in rheumatoid arthritis (RA) patients.Methods: Plasma proteins (n = 163) were profiled in 44 patients with RA diagnosed according to the American College of Rheumatology 1987 criteria (22 with active and 22 with quiescent disease) and in 16 age‐ and sex‐matched healthy controls. The utility of a subset of differentially expressed proteins as predictors of RA disease activity was investigated using partial least‐squares discriminant analysis, and their response to therapeutic intervention was evaluated in plasma from an additional cohort of 16 patients with active RA treated with anti–tumor necrosis factor α (anti‐TNFα).Results: The protein profiling study identified 25 proteins that were differentially expressed in plasma samples from patients with active RA (P for the false discovery rate ≤ 0.01) compared with those with quiescent RA, including the previously described interleukin‐6 (IL‐6), oncostatin M, and IL‐2, and the 5 less‐established markers macrophage colony‐stimulating factor (M‐CSF), tumor necrosis factor receptor superfamily member 9, CCL23, transforming growth factor α, and CXCL13. Systemic levels of these 5 markers correlated with the C‐reactive protein level, erythrocyte sedimentation rate, rheumatoid factor level, tender joint count in 68 joints, and Disease Activity Score in 28 joints (DAS28), and their combined plasma levels were shown to be good predictors of disease activity (κ = 0.64). In anti‐TNFα–treated RA patients, plasma levels of CXCL13 were reduced after 1 and 7 days of therapy, and levels of CCL23, M‐CSF, and CXCL13 showed a statistically significant positive correlation with the DAS28 score.Conclusion: This exploratory study for biomarker discovery led to the identification of several proteins predictive of RA disease activity that may be useful in the definition of disease subphenotypes and in the measurement of response to therapy in clinical studies.Keywords
This publication has 32 references indexed in Scilit:
- Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in JapanAnnals of the Rheumatic Diseases, 2007
- Sample size calculation with dependence adjustment for FDR-control in microarray studiesStatistics in Medicine, 2007
- A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2004
- Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritisExperimental & Molecular Medicine, 2004
- Expression of the Activation Antigen CD27 in Rheumatoid ArthritisClinical Immunology and Immunopathology, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1994
- Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritidesArthritis & Rheumatism, 1988
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988